Skip to main content
. Author manuscript; available in PMC: 2022 Dec 12.
Published in final edited form as: Ann Oncol. 2019 Dec 9;31(3):412–421. doi: 10.1016/j.annonc.2019.11.018

Figure 1. Time on treatment and (B) best change in target lesion size by patient.

Figure 1.

(A) (n = 19).a CR, complete response; HER2, human epidermal growth factor receptor 2; Hh, Hedgehog; PD, progressive disease; PR, partial response; PTCH-1, patched homolog-1; SD, stable disease; TMB, tumor mutational burden.

a Lanes represent individual patients.